

IMAGING PERFORMED BY

IntraPet.com



Clinical Sonography & Telecytology

EDUCATIONAL TELECONSULTATION SERVICES™

1-800-838-4268 info@sonopath.com SonoPath.com

PATIENT

Nathaniel Hawthorne Reid

SPECIES

Feline

BREED

DLH

SEX

Male Neutered

AGE

7.11.04

WEIGHT

10lbs

INTERPRETED BY

Maggie Machen Lamy, DVM, DACVIM (Cardiology)

HOSPITAL NAME

Harborside Mobile Veterinary Clinic

REFERRING VET

Dr. Hawkins

INVOICE

23854

DATE

4.25.22

PRESENTING CLINICAL SIGNS

History: Recheck echo.

-Current medications: Vetmedin 1.25mg BID, Prednisolone 5mg SID, Benazepril 2.5mg BID, Plavix 18.75mg SID.

-Sedation used: Not required to complete full diagnostic ultrasound.

-Pertinent previous ultrasound results (7/2021 MML): Moderate to severe MR, moderate to severe LAE, moderate LVE, no TR. LV: 2.4, LA: 1.6, LA/AO: 1.9.

-STAT: Not requested

-Imaging performed by: Stephanie Pearce RDCS, RVT.

ECHOCARDIOGRAM FINDINGS

2D, m-mode, color flow and doppler imaging is available. The mitral valve leaflets are thickened with septal prolapse. Moderate eccentric mitral regurgitation with moderate left atrial dilation. Minimal LV dilation with adequate myocardial function. LV walls are normal in diameter. The tricuspid valve appears normal with no tricuspid regurgitation. Normal right atrial and ventricular diameter and morphology indicating no overt evidence of pulmonary arterial hypertension. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities with laminar flow. No obvious aortic or pulmonic insufficiency. No pericardial or pleural effusion noted. No obvious cardiac masses.

CARDIAC CHART

FELINE CARDIAC PARAMETERS	BODY WEIGHT (kg)	HR (BPM)	IVSd (cm) (Moise, Pipers)	LVIDd (cm) (Moise, Pipers)	LWVd (cm) (Moise, Pipers)	FS (%)	EF (%)
NORMAL PARAMETER	-----	150-240	3.5-0.55	<2 (mean 1.5)	3.5-0.55	35-67	80-100
PATIENT	4.5	NM	0.4	1.7	0.4	45	80
FELINE CARDIAC PARAMETERS	LA/AO (Boon)	LA/AO HEART BASE (Swe) (Abbott)	LA 2D short axis Base view (cm) (Abbott)	LVOT VEL (m/s)	RVOT VEL (m/s)	E max (m/s)	
NORMAL	<1.5	<1.3	<1.2	<1.6	<1.3	<0.9	
PATIENT	NM	1.8	1.6	1.2	1.2	NM	

Adapted from June Boon, Veterinary Echocardiography, 1998
 Abbott J & MacLean H JVIM 2006;20: 111-119, Moise et al. Am J Vet Res 47:1476, 1986. Pipers et al. Am J Vet Res 40:882, 1979.

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Moderate mitral regurgitation persists with evidence of stability. The LA dimension is unchanged, and the LV is slightly improved. This is presumably due to medical management with Pimobendan. No additional issues are identified at this time.

Prognosis remains guarded going forward. Given these findings, there will always remain risk for progression to CHF and development of blood clots in the future. Monitoring of sleeping breathing rates at home is recommended as the best way to screen for recurrent CHF at home.

Anesthetic risk is considered elevated.


Monitor at home for any respiratory signs, syncope, or signs of a blood clot event (paralysis, lameness, neurologic change).

PLAN

Continue Pimobendan, Benazepril and Plavix as prescribed.

A recheck echocardiogram is recommended in 6 months to assess for progression.

IMAGES



The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com